Hydrofluoric Acid-Based Derivatization Strategy To Profile PARP-1 ADP-Ribosylation by LC-MS/MS.
Jean-Philippe GagnéMarie-France LangelierJohn M PascalGuy G PoirierPublished in: Journal of proteome research (2018)
Despite significant advances in the development of mass spectrometry-based methods for the identification of protein ADP-ribosylation, current protocols suffer from several drawbacks that preclude their widespread applicability. Given the intrinsic heterogeneous nature of poly(ADP-ribose), a number of strategies have been developed to generate simple derivatives for effective interrogation of protein databases and site-specific localization of the modified residues. Currently, the generation of spectral signatures indicative of ADP-ribosylation rely on chemical or enzymatic conversion of the modification to a single mass increment. Still, limitations arise from the lability of the poly(ADP-ribose) remnant during tandem mass spectrometry, the varying susceptibilities of different ADP-ribose-protein bonds to chemical hydrolysis, or the context dependence of enzyme-catalyzed reactions. Here, we present a chemical-based derivatization method applicable to the confident identification of site-specific ADP-ribosylation by conventional mass spectrometry on any targeted amino acid residue. Using PARP-1 as a model protein, we report that treatment of ADP-ribosylated peptides with hydrofluoric acid generates a specific +132 Da mass signature that corresponds to the decomposition of mono- and poly(ADP-ribosylated) peptides into ribose adducts as a consequence of the cleavage of the phosphorus-oxygen bonds.
Keyphrases
- amino acid
- liquid chromatography
- mass spectrometry
- high performance liquid chromatography
- tandem mass spectrometry
- gas chromatography
- simultaneous determination
- high resolution
- protein protein
- ms ms
- binding protein
- magnetic resonance imaging
- magnetic resonance
- optical coherence tomography
- oxidative stress
- gas chromatography mass spectrometry
- small molecule
- big data
- cancer therapy
- dna methylation